Parexel Expands Global Regulatory Capabilities with Experts from FDA, EMA, NMPA and Spanish AEMPS
BOSTON and DURHAM, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today announced the addition of former regulators with significant expertise in oncology, immunotherapy and rare disease to its Regulatory & Access Consulting team, further supporting the advancement of new treatments for patients worldwide.
“The global pandemic has created a highly dynamic regulatory environment as companies adapt quickly to protect patients, preserve supply chains and maintain focus on new emerging therapies,” said Paul Bridges, Senior Vice President, Regulatory & Access. “Parexel remains committed now, more than ever, to helping our customers address the rapidly evolving regulatory changes through a strong roster of former regulators and regulatory experts. Our new colleagues bring first-hand experience from their tenure working within global health authorities to help our customers seamlessly navigate the regulatory process and ultimately help deliver new therapies to patients.”
The new team members will serve as Technical Vice Presidents and join Parexel’s group of more than 1,000 consulting experts whose combined knowledge, skill and experience in quality and compliance expertly guide customers through complex global and in-country regulations. They will provide their perspective on key aspects of the regulatory process, including navigating rapidly evolving landscapes related to regulatory meetings and submissions, compliance and market access. The recent appointments include:
Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.
Parexel is a registered trademark of Parexel International Corporation. All other trademarks are the property of their respective owners.
IoT Security Against Global Cybercrime
Key Tools of the IoT Security Trade